Last reviewed · How we verify
Artificial Saliva
At a glance
| Generic name | Artificial Saliva |
|---|---|
| Also known as | pilocarpine |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Integrated Oral Care Intervention for Xerostomia in Diabetes Patients (NA)
- Interventions for Patients With Alzheimer's Disease and Dysphagia (NA)
- Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care
- Effect of Cold Application and Artificial Saliva in the Prevention of Chemotherapy-Induced Oral Mucositis (NA)
- Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
- Effect of Treatments on Pain and Quality of Life in Individual With Burning Mouth Syndrome (PHASE4)
- A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) (PHASE2)
- Oral and Swallowing Function in Older Adults
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Artificial Saliva CI brief — competitive landscape report
- Artificial Saliva updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI